LYKALABSPharmaceuticals
Lyka Labs Ltd — Cash Flow Statement
₹44.95
-9.04%
Lyka Labs Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -13.76 Cr | -7.46 Cr | 0.77 Cr | 71.73 Cr | — |
| Issuance Of Capital Stock | 27.20 Cr | 25.11 Cr | 45.34 Cr | 0.00 | — |
| Capital Expenditure | -15.65 Cr | -9.23 Cr | -8.19 Cr | -7.51 Cr | — |
| End Cash Position | 1.34 Cr | 5.95 Cr | 11.71 Cr | 17.05 Cr | — |
| Other Cash Adjustment Outside Changein Cash | -1000.00 | -1000.00 | — | 1000.00 | -1000.00 |
| Beginning Cash Position | 5.95 Cr | 11.71 Cr | 17.05 Cr | 7.15 Cr | — |
| Changes In Cash | -4.60 Cr | -5.76 Cr | -5.34 Cr | 9.90 Cr | — |
| Financing Cash Flow | 5.29 Cr | 1.95 Cr | -21.64 Cr | -63.18 Cr | — |
| Interest Paid Cff | -2.44 Cr | -7.17 Cr | -10.20 Cr | -22.99 Cr | — |
| Net Common Stock Issuance | 27.20 Cr | 25.11 Cr | 45.34 Cr | 0.00 | — |
| Common Stock Issuance | 27.20 Cr | 25.11 Cr | 45.34 Cr | 0.00 | — |
| Net Issuance Payments Of Debt | -19.47 Cr | -15.98 Cr | -56.78 Cr | -40.19 Cr | — |
| Net Short Term Debt Issuance | 4.80 Cr | 5.72 Cr | -11.95 Cr | 9.58 Cr | — |
| Net Long Term Debt Issuance | -24.27 Cr | -21.71 Cr | -44.83 Cr | -49.77 Cr | — |
| Investing Cash Flow | -11.80 Cr | -9.49 Cr | 7.35 Cr | -6.17 Cr | — |
| Interest Received Cfi | 0.46 Cr | -0.26 Cr | 1.04 Cr | 1.34 Cr | — |
| Net Investment Purchase And Sale | 0.08 Cr | 0.00 | — | — | — |
| Sale Of Investment | 0.08 Cr | 0.00 | — | — | — |
| Net PPE Purchase And Sale | -12.34 Cr | -9.23 Cr | 6.31 Cr | -7.51 Cr | — |
| Sale Of PPE | 3.32 Cr | 0.00 | 14.50 Cr | 0.00 | — |
| Purchase Of PPE | -15.65 Cr | -9.23 Cr | -8.19 Cr | -7.51 Cr | — |
| Operating Cash Flow | 1.90 Cr | 1.77 Cr | 8.95 Cr | 79.25 Cr | — |
| Taxes Refund Paid | -3.03 Cr | -1.52 Cr | 0.20 Cr | -0.92 Cr | — |
| Change In Working Capital | -14.65 Cr | -13.80 Cr | -9.86 Cr | -21.01 Cr | — |
| Change In Other Current Liabilities | 1.61 Cr | -1.34 Cr | -7.48 Cr | -0.60 Cr | — |
| Change In Other Current Assets | 0.71 Cr | -5.38 Cr | 1.71 Cr | -3.45 Cr | — |
| Change In Payable | 2.85 Cr | 2.70 Cr | -2.59 Cr | -2.72 Cr | — |
| Change In Inventory | -2.89 Cr | -2.62 Cr | 1.24 Cr | -3.89 Cr | — |
| Change In Receivables | -15.18 Cr | -6.31 Cr | -1.25 Cr | -9.09 Cr | — |
| Other Non Cash Items | 1.81 Cr | 5.15 Cr | 17.50 Cr | 24.58 Cr | — |
| Provisionand Write Offof Assets | 0.93 Cr | 0.57 Cr | 0.53 Cr | 0.53 Cr | — |
| Depreciation And Amortization | 6.77 Cr | 12.80 Cr | 14.15 Cr | 17.35 Cr | — |
| Amortization Cash Flow | 2.92 Cr | 8.97 Cr | 8.78 Cr | — | — |
| Depreciation | 3.85 Cr | 12.80 Cr | 14.15 Cr | 17.35 Cr | — |
| Gain Loss On Investment Securities | -0.03 Cr | -87000.00 | -4000.00 | -3000.00 | — |
| Net Foreign Currency Exchange Gain Loss | -1.02 Cr | -0.49 Cr | -0.40 Cr | -0.53 Cr | — |
| Net Income From Continuing Operations | 11.12 Cr | -0.93 Cr | -13.17 Cr | 59.25 Cr | — |
| Net Other Financing Charges | — | — | — | -1000.00 | — |
| Repayment Of Debt | — | — | — | — | -4.85 Cr |
| Short Term Debt Payments | — | — | — | — | -4.85 Cr |
| Capital Expenditure Reported | — | — | — | — | -1.27 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Lyka Labs Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.